Nikita Sinha

No ORCID on file · 1 paper in corpus

lab-animal 2025

Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer

Frontiers in pharmacology ·doi:10.3389/fphar.2025.1520771

OBJECTIVE: Chronic inflammation is a key contributor to carcinogenesis, progression, and chemoresistance in ovarian cancer, making inflammatory pathways a logical therapeutic target for the treatment of this disease. Sulindac, a commonly us…